ReviewStem cells translational medicine2015
Concise review: making and using clinically compliant pluripotent stem cell lines.
Review in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Trial
- Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU.Frontiers in medicine · 2026Review
- RFX6 regulates human intestinal patterning and function upstream of PDX1.Development (Cambridge, England) · 2024Article
- Differentiation of placenta-derived MSCs cultured in human platelet lysate: a xenofree supplement.3 Biotech · 2024Article
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Stem Cell-Based Therapies: What Interventional Radiologists Need to Know.Seminars in interventional radiology · 2021Review
- Developing standards to support the clinical translation of stem cells.Stem cells translational medicine · 2021Review
- Review
- Automating Human Induced Pluripotent Stem Cell Culture and Differentiation of iPSC-Derived Retinal Pigment Epithelium for Personalized Drug Testing.SLAS technology · 2021Article
- Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.Stem cells translational medicine · 2021Review
- Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.Advances in experimental medicine and biology · 2021Review
- The Rho-associated kinase inhibitor fasudil can replace Y-27632 for use in human pluripotent stem cell research.PloS one · 2020Article
- An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy.Stem cell research & therapy · 2019Review
- Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies.Trends in molecular medicine · 2019Review
- Shifting gears from embryonic to very small embryonic-like stem cells for regenerative medicine.The Indian journal of medical research · 2017Article
- PAX7 Targets, CD54, Integrin α9β1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors.Cell reports · 2017Article
- Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications.Stem cell reviews and reports · 2016Article
- Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.Regenerative therapy · 2016Review
- Developing Induced Pluripotent Stem Cell-Based Therapy for the Masses.Stem cells translational medicine · 2016Article
- cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.Stem cell reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of pluripotent stem cells (PSCs) is in a state of dynamic flux driven by significant advances in the derivation of specific phenotypes from embryonic stem cells, breakthroughs in somatic cell nuclear transfer, and dramatic improvements in generating induced PSCs using zero footprint methods. Spurred by these technological advances, companies have begun to plan clinical studies using human PSC derivatives manufactured in current Good Manufacturing Practice-compliant conditions. In the present review, we discuss the challenges in making these biological products, starting from tissue sourcing to the processes involved in manufacture, storage, and distribution. Additional challenges exist to meeting the regulatory requirements and keeping costs affordable. A model is described that has been proposed by the U.S. National Institutes of Health for reducing the costs and permitting flexibility and innovation by individual investigators. This model, combined with small adjustments in the regulatory processes tailored to address the unique properties of PSCs, has the potential of significantly accelerating the implementation of PSC-based cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.